攝護腺癌賀爾蒙治療與新診斷糖尿病的關聯性
詹鎮豪1、葉信志1,2,3、張郁函3、古筱菁1、吳文正1,2,3、周以和1,2、李經家1,2
1高雄醫學大學附設醫院 泌尿部
2高雄醫學大學 醫學系
3高雄市立大同醫院
New-Onset Diabetes After Androgen-Deprivation Therapy For Prostate Cancer: A Nationwide Propensity Score-Matched Four-Year Longitudinal Cohort Study
Jhen-Hao Jhan1, Hsin-Chih Yeh1,2,3, Yu-Han Chang3, Shiao-Jin Guu1, Wen-Jeng Wu1,2,3,
Yii-Her Chou1,2, Ching-Chia Li1,2
1Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
2Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
3Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan
Introduction: Androgen-deprivation therapy (ADT) is important in the treatment of prostate cancer. However, the relationship between ADT and the risk of diabetes remains unclear, and the association between duration and types of ADT has not been fully investigated.
Aim: To examine the risk of developing type 2 diabetes mellitus (T2DM) in men who underwent ADT for prostate cancer.
Methods: Data were collected retrospectively from the Longitudinal Health Insurance Database of Taiwan. In total, 4604 prostate cancer patients ≥ 40 years old who underwent ADT were included in the study cohort, and 4604 prostate cancer patients without ADT were included as controls, after adjusting for age and other comorbidities.
Results: During the four-year follow-up period, the incidence of new-onset T2DM was 27.49 and 11.13 per 1000 person-years in the ADT and ADT-never cohorts, respectively. The ADT cohort was 2.19 times more likely to develop T2DM than the control group (95% CI 1.90–2.53, P < 0.001). Furthermore, the association was particularly striking in the subgroup of patients receiving complete androgen blockade (adjusted HR 2.33, 95% CI 1.96–2.78, P < 0.001).
Conclusions: Men with prostate cancer who received ADT are at risk for developing diabetes.